These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31657609)

  • 1. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH).
    Crespo J; Albillos A; Buti M; Calleja JL; García Samaniego J; Hernández Guerra M; Serrano T; Turnes J; Acín E; Berenguer J; Berenguer M; Colom J; Fernández I; Fernández Rodríguez C; Forns X; García F; Grandados R; Lazarus JV; Molero JM; Molina E; Pérez Escanilla F; Pineda JA; Rodríguez M; Romero M; Roncero C; Saiz de la Hoya P; Sánchez Antolín G
    Rev Esp Enferm Dig; 2019 Nov; 111(11):862-873. PubMed ID: 31657609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH).
    Crespo J; Albillos A; Buti M; Calleja JL; García-Samaniego J; Hernández-Guerra M; Serrano T; Turnes J; Acín E; Berenguer J; Berenguer M; Colom J; Fernández I; Fernández Rodríguez C; Forns X; García F; Rafael Granados ; Lazarus JV; Molero JM; Molina E; Pérez Escanilla F; Pineda JA; Rodríguez M; Romero M; Roncero C; Saiz de la Hoya P; Sánchez Antolín G
    Gastroenterol Hepatol; 2019 Nov; 42(9):579-592. PubMed ID: 31594683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Milestones to reach Hepatitis C Virus (HCV) elimination in Italy: From free-of-charge screening to regional roadmaps for an HCV-free nation.
    Kondili LA; Aghemo A; Andreoni M; Galli M; Rossi A; Babudieri S; Nava F; Leonardi C; Mennini FS; Gardini I; Russo FP
    Dig Liver Dis; 2022 Feb; 54(2):237-242. PubMed ID: 33926816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
    Kondili LA; Blach S; Razavi H; Craxì A
    Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.
    Akiyama MJ; Kronfli N; Cabezas J; Sheehan Y; Thurairajah PH; Lines R; Lloyd AR;
    Lancet Gastroenterol Hepatol; 2021 May; 6(5):391-400. PubMed ID: 33857445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovations in Hepatitis C Screening and Treatment.
    Patel AA; Bui A; Prohl E; Bhattacharya D; Wang S; Branch AD; Perumalswami PV
    Hepatol Commun; 2021 Mar; 5(3):371-386. PubMed ID: 33681673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies.
    Krauth C; Rossol S; Ortsäter G; Kautz A; Krüger K; Herder B; Stahmeyer JT
    BMC Infect Dis; 2019 Dec; 19(1):1019. PubMed ID: 31791253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt.
    Esmat G; Elbaz T; Elsharkawy A; Abdullah M; El Kassas M
    Expert Rev Anti Infect Ther; 2020 Jul; 18(7):637-642. PubMed ID: 32302245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absolute targets for HCV elimination and national health policy paradigms: Foreseeing future requirements.
    Kondili LA; Craxì A; Aghemo A
    Liver Int; 2021 Apr; 41(4):649-655. PubMed ID: 33486885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
    Papatheodoridis GV; Hatzakis A; Cholongitas E; Baptista-Leite R; Baskozos I; Chhatwal J; Colombo M; Cortez-Pinto H; Craxi A; Goldberg D; Gore C; Kautz A; Lazarus JV; Mendão L; Peck-Radosavljevic M; Razavi H; Schatz E; Tözün N; van Damme P; Wedemeyer H; Yazdanpanah Y; Zuure F; Manns MP
    J Viral Hepat; 2018 Mar; 25 Suppl 1():6-17. PubMed ID: 29508946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remaining challenges in HCV elimination.
    Capraru C; Feld JJ
    J Hepatol; 2021 Apr; 74(4):964-965. PubMed ID: 33589319
    [No Abstract]   [Full Text] [Related]  

  • 13. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
    PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    European Union HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the Cherokee Nation Hepatitis C Virus Elimination Program in the First 22 Months of Implementation.
    Mera J; Williams MB; Essex W; McGrew KM; Boeckman L; Gahn D; Miller A; Durham D; Fox J; David C; Ritter T; Jones S; Bouse S; Galvani A; Ward JW; Drevets DA; Carabin H
    JAMA Netw Open; 2020 Dec; 3(12):e2030427. PubMed ID: 33337496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying the lower age limit for hepatitis C screening in large elimination programmes in highly endemic areas.
    Hamid S; Abid A; Dore GJ
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):89-90. PubMed ID: 33444535
    [No Abstract]   [Full Text] [Related]  

  • 17. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Is Needed to Eliminate Hepatitis B Virus and Hepatitis C Virus as Global Health Threats.
    Ward JW; Hinman AR
    Gastroenterology; 2019 Jan; 156(2):297-310. PubMed ID: 30391470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination.
    Hagan LM; Kasradze A; Salyer SJ; Gamkrelidze A; Alkhazashvili M; Chanturia G; Chitadze N; Sukhiashvili R; Shakhnazarova M; Russell S; Blanton C; Kuchukhidze G; Baliashvili D; Hariri S; Ko S; Imnadze P; Drobeniuc J; Morgan J; Averhoff F
    BMC Public Health; 2019 May; 19(Suppl 3):480. PubMed ID: 32326913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eliminating viral hepatitis C in Belgium: the micro-elimination approach.
    Busschots D; Toghanian S; Bielen R; Salomonsson S; Koc ÖM; Hendrickx G; Jadoul M; Nevens F; Sokal E; Brixko C; Peerlinck K; Apers L; Robaeys G; Lazarus JV
    BMC Infect Dis; 2020 Feb; 20(1):181. PubMed ID: 32106819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.